https://thedigestlab.com/press-releases/johnson-and-johnson-announces-new-phase-2-nipocalimab-study-data-in-sjogrens-disease-thatThe Digest Laben2026-11-07T15:06:02.858ZJohnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients https://thedigestlab.com/press-releases/us-fda-approves-rybrevant-fasprotm-amivantamab-and-hyaluronidase-lpuj-co-formulated-withThe Digest Laben2026-11-06T15:21:42.336ZU.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer https://thedigestlab.com/press-releases/johnson-and-johnson-announces-us-fda-approval-of-rybrevant-fasprotm-amivantamab-andThe Digest Laben2026-11-06T02:14:41.787ZJohnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer